Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Lenalidomide, bortezomib, and dexamethasone (RVd) followed by autologous stem cell transplantation (ASCT) is standard frontline therapy for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). The addition of daratumumab (D) to RVd (D-RVd) in transplant-eligible NDMM patients w...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood
Main Authors: Voorhees, Peter M., Kaufman, Jonathan L., Laubach, Jacob, Sborov, Douglas W., Reeves, Brandi, Rodriguez, Cesar, Chari, Ajai, Silbermann, Rebecca, Costa, Luciano J., Anderson, Larry D., Nathwani, Nitya, Shah, Nina, Efebera, Yvonne A., Holstein, Sarah A., Costello, Caitlin, Jakubowiak, Andrzej, Wildes, Tanya M., Orlowski, Robert Z., Shain, Kenneth H., Cowan, Andrew J., Murphy, Sean, Lutska, Yana, Pei, Huiling, Ukropec, Jon, Vermeulen, Jessica, de Boer, Carla, Hoehn, Daniela, Lin, Thomas S., Richardson, Paul G.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2020
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7441167/
https://ncbi.nlm.nih.gov/pubmed/32325490
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020005288
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares